Larimar Therapeutics Shares Surge 34% After FDA Grants Breakthrough Therapy Designation

Larimar Therapeutics, Inc. (LRMR) shares soared 34.34 percent to $3.77, up $0.96 on Tuesday, after the company announced that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to nomlabofusp for the treatment of Friedreich's ataxia. The stock is currently trading at $3.9200, compared with a previous close of $2.8100. It opened at $3.5900 and has traded between $3.5500 and $4.0000 during the session. Trading volume has surged to 43.95 million shares, far exceeding its average vo ...